Moexipril 15mg tablets

Studies have shown that angiotensin converting enzyme inhibitors (ACEIs) are superior in primary and secondary prevention for cardiac mortality and morbidity to angiotensin receptor blocker (ARBs). One of the common side effects from ACEI is dry cough. The aims of this systematic review, and network meta-analysis are to rank the risk of cough induced by different ACEIs and between ACEI and placebo, ARB or calcium channel blockers (CCB). We performed a systematic review, and network meta-analysis of randomized controlled trials to rank the risk of cough induced by each ACEI and between ACEI and placebo, ARB or CCB. A total of 135 RCTs with 45,420 patients treated with eleven ACEIs were included in the analyses. The pooled estimated relative risk (RR) between ACEI and placebo was 2.21 (95% CI: 2.05-2.39). ACEI had more incidences of cough than ARB (RR 3.2; 95% CI: 2.91, 3.51), and pooled estimated of RR between ACEI and CCB was 5.30 (95% CI: 4.32-6.50) Moexipril ranked as number one for inducing cough (SUCRA 80.4%) and spirapril ranked the least (SUCRA 12.3%). The order for the rest of the ACEIs are as follows: ramipril (SUCRA 76.4%), fosinopril (SUCRA 72.5%), lisinopril (SUCRA 64.7%), benazepril (SUCRA 58.6%), quinapril (SUCRA 56.5%), perindopril (SUCRA 54.1%), enalapril (SUCRA 49.7%), trandolapril (SUCRA 44.6%) and, captopril (SUCRA 13.7%). All ACEI has the similar risk of developing a cough. ACEI should be avoided in patients who have risk of developing cough, and an ARB or CCB is an alternative based on the patient's comorbidity.

Abstract licence: CC BY

Objective: The goal of this study is to see if moexipril can protect rats against renal ischemia/reperfusion injury. Methods: Overall twenty-eight males of rats were divided randomly into four groups (7 rat each group). Sham group: Except for ischemiainduction, these rats underwent IP anesthesia and surgery. Induced group: This group rats were anesthetized and given a midlinelaparotomy to induce bilateral renal ischemia for 30 min and 2 hours of reperfusion. DMSO group: Rats received DMSO IP injection 30 minbefore ischemia and subjected to 30 min bilateral ischemia and reperfusion for 2 hours, DMSO is a vehicle of moexipril and considered ascontrol. Moexipril group (pretreated group): moexipril was given in a dose 0.3 mg/kg I.P. injection 30 min before ischemia. Results: Renal IRI as indicated by a significant increase (P < 0.05) in urea, creatinine, NF-KB P65, IL-1β, and caspase-3 level, while GSH,SOD, and Bcl-2 levels significantly (P < 0.05) reduced in Renal tissues of rats in the induced group compared to sham group. Moexiprilpretreatment significantly (P < 0.05) ameliorate RIRI as suggested from significant lowering in urea, creatinine, and inflammatory markers(NF-KB P65 and IL-1β). The renal level of oxidative marker (SOD and GSH) and anti-apoptotic marker Bcl-2 were significant decreased(P < 0.05) and also significantly increase (P < 0.05) in caspase-3 level with moexipril group in comparison to induced group. Conclusion: By inhibiting oxidative stress, inflammation, and the apoptotic pathway, moexipril significantly protect from renal ischemiareperfusion in rats.

Abstract licence: CC BY-NC

• Cutting Edge Self-Emissive Fluorescence: Capitalizing Moexipril fluorescence • Ultrafast microwave-assisted synthesis of N, S-CQDs from Arugula leaves • Bio-Inspired Nanomaterial Innovation: Pioneering the use of Arugula leaves N, S-CQDs • Real World Applications: Methods ensure innovative performance in complex matrices • Eco-Conscious Advancement: The method design aligns with green chemistry principles . Monitoring the level of Moexipril is crucial for hypertensive patients, therefore two environmentally friendly, rapid and selective analytical techniques have been established for its sensitive measurement. First method relies on direct measurement of its native fluorescence at λ ex 282 nm / λ em 315 nm. The second method is based on the efficient and quantitative enhancement of N, S-CQDs fluorescence intensity by Moexipril in the presence of 1% Tween. The remarkably fluorescent N and S-CQDs were developed via 8 minutes microwave-aided one-pot synthesis using promising, cheap and widely available precursors (Arugula leaves) for the first time. The sensor is characterized by excellent doping efficiency (N, 13.01% and S, 12.39%), narrow particle size distribution (2.7±0.6 nm), reproducibility and good fluorescence at λ ex 320nm / λ em 430 nm with 68.5% quantum yield. Also, the designed probe selectivity was verified in presence of possible co-existing excipients, various metal ions and co-administered drugs that grants the practical applicability of N, S-CQDs as an environmental probe. Additionally, both methods showed excellent linearity (r = 0.9999) within the specified concentrations range (0.02-0.6 and 0.004-0.7 µg/mL for method I and II, respectively) and they were implemented for the analysis of Moexipril in pharmaceutical tablets and biological fluids, yielding high recovery percentages. The proposed procedures were fully validated in compliance with the ICH Guidelines. Moreover, the greenness, blueness and whiteness profiles of developed methods were evaluated for accomplishment of a complete ecological profile of the designed fluorimetric methodologies and the excellent obtained results confirmed their excellent eco friendless, good applicability and sustainability. .

Abstract licence: CC BY-NC

Background and objective: Angiotensin-converting enzyme inhibitors are first-line therapies for hypertension and related cardiovascular and renal conditions. The study aimed to characterize the adverse event profile of ACE inhibitors using the U.S. Food and Drug Administration Adverse Event Reporting System. Methods: This retrospective pharmacovigilance study analyzed FAERS reports submitted from January 1, 1979, through March 31, 2025, for nine ACE inhibitors (benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, quinapril, ramipril, and trandolapril) identified as primary suspect drugs. Extracted variables included patient age, sex, reporter type, and reported adverse events. Descriptive statistics were used to summarize reporting frequencies. Comparisons between subgroups (male vs female, <18 vs ≥18 years, and healthcare professional vs consumer reporters) were conducted using reporting proportions. Reporting proportion ratios (RPRs) were calculated to compare the proportion of specific adverse events between predefined reference categories. As FAERS does not provide denominator data, findings reflect reporting patterns rather than incidence or risk estimates. Results: A total of 124,638 adverse event reports were identified. ADEs were disproportionately higher in adults and elderly patients compared to those <18 years. Males generally reported more ADEs than females, though some drugs showed the opposite trend. Healthcare professionals submitted the majority of reports (pooled RR = 2.22, 95% CI: 2.20-2.25). The most commonly reported ADEs were angioedema, cough, hypotension, and acute kidney injury. Conclusion: ACE inhibitor adverse event profiles vary by drug, patient age, and sex. Adults and elderly patients carry the highest burden of ADEs, though pediatric cases remain clinically relevant for specific agents. These findings support tailored monitoring and risk mitigation strategies in clinical practice.

Abstract licence: CC BY-NC